The current Hodgkin lymphoma immunotherapy landscape

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, provides an overview of current and future Hodgkin lymphoma immunotherapies. PD-1 inhibitors have been effective in treating Hodgkin lymphoma and additional approaches have been developed. Camidanlumab tesirine is a novel antibody-drug conjugate (ADC) in development that targets regulatory T cells as well as Reed–Sternberg cells and consists of an anti-CD25 monoclonal antibody and a cytotoxin. The novel ADC has been effective in patients who are refractory to chemotherapy and PD-1 inhibitors and is a promising Hodgkin lymphoma drug despite initial toxicities reported. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).